Epharmix Revenue and Competitors
Estimated Revenue & Valuation
- Epharmix's estimated annual revenue is currently $18.2M per year.
- Epharmix's estimated revenue per employee is $243,000
Employee Data
- Epharmix has 75 Employees.
- Epharmix grew their employee count by 21% last year.
Epharmix's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Developer | Reveal Email/Phone |
2 | Creative Director | Reveal Email/Phone |
3 | Graphic Designer | Reveal Email/Phone |
4 | Growth Engineer | Reveal Email/Phone |
Epharmix Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $9.7M | 45 | 5% | N/A | N/A |
#2 | $558.3M | 1477 | 7% | N/A | N/A |
#3 | $9.7M | 45 | 10% | N/A | N/A |
#4 | $9.7M | 45 | 2% | N/A | N/A |
#5 | $23M | 85 | 5% | N/A | N/A |
#6 | $4.2M | 22 | 5% | N/A | N/A |
#7 | $51.7M | 174 | 1% | N/A | N/A |
#8 | $13.1M | 54 | 0% | N/A | N/A |
#9 | $8M | 37 | 6% | N/A | N/A |
#10 | $29.2M | 108 | 16% | N/A | N/A |
What Is Epharmix?
Epharmix helps your care management team improve health outcomes by engaging high and rising-risk patients. Our scalable, automated call and text platform collects patient-reported health status between regular visits to identify rising-risk patients, enabling your clinical team to prevent costly hospitalizations or exacerbations. We support 24 chronic and behavioral health conditions, offering a holistic approach to addressing co-morbidities with one evidence-based tool that is aligned with quality metrics to meet your organizations evolving business goals. Self-guided Demo: https://try.epharmix.com/ Learn More: https://www.epharmix.com/
keywords:N/AN/A
Total Funding
75
Number of Employees
$18.2M
Revenue (est)
21%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $9.8M | 75 | 27% | N/A |
#2 | $14.2M | 75 | 39% | N/A |
#3 | $20.5M | 76 | 3% | N/A |
#4 | $15M | 76 | 27% | N/A |
#5 | $18.6M | 76 | 29% | N/A |